Literature DB >> 17408693

Association of schizophrenia with DTNBP1 but not with DAO, DAOA, NRG1 and RGS4 nor their genetic interaction.

Elisabet Vilella1, Javier Costas, Julio Sanjuan, Míriam Guitart, Yolanda De Diego, Angel Carracedo, Lourdes Martorell, Joaquín Valero, Antonio Labad, Rosa De Frutos, Carmen Nájera, M Dolores Moltó, Ivette Toirac, Roser Guillamat, Anna Brunet, Vicenç Vallès, Lucía Pérez, Melquíades Leon, Fernando Rodríguez de Fonseca, Christopher Phillips, María Torres.   

Abstract

Recent reports indicate that DAO, DAOA, DTNBP1, NRG1 and RGS4 are some of the most-replicated genes implicated in susceptibility to schizophrenia. Also, the functions of these genes could converge in a common pathway of glutamate metabolism. The aim of this study was to evaluate if each of these genes, or their interaction, was associated with schizophrenia. A case-control study was conducted in 589 Spanish patients having a diagnosis of schizophrenia, and compared with 617 equivalent control subjects. Several single nucleotide polymorphisms (SNPs) in each gene were determined in all individuals. SNP and haplotype frequencies were compared between cases and controls. The interaction between different SNPs at the same, or at different gene, loci was analyzed by the multifactor dimensionality reduction (MDR) method. We found a new schizophrenia risk and protective haplotypes in intron VII of DTNBP1; one of the most important candidate genes for this disorder, to-date. However, no association was found between DAO, DAOA, NRG1 and RGS4 and schizophrenia. The hypothesis that gene-gene interaction in these five genes could increase the risk for the disorder was not confirmed in the present study. In summary, these results may provide further support for an association between the dysbindin gene (DTNBP1) and schizophrenia, but not between the disease and DAO, DAOA, NRG1 and RGS4 or with the interaction of these genes. In the light of recent data, these results need to be interpreted with caution and future analyses with dense genetic maps are awaited.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17408693     DOI: 10.1016/j.jpsychires.2007.02.005

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  32 in total

1.  Biological validation of increased schizophrenia risk with NRG1, ERBB4, and AKT1 epistasis via functional neuroimaging in healthy controls.

Authors:  Kristin K Nicodemus; Amanda J Law; Eugenia Radulescu; Augustin Luna; Bhaskar Kolachana; Radhakrishna Vakkalanka; Dan Rujescu; Ina Giegling; Richard E Straub; Kate McGee; Bert Gold; Michael Dean; Pierandrea Muglia; Joseph H Callicott; Hao-Yang Tan; Daniel R Weinberger
Journal:  Arch Gen Psychiatry       Date:  2010-10

2.  Association between RGS4 variants and psychotic-like experiences in nonclinical individuals.

Authors:  Marta de Castro-Catala; Paula Cristóbal-Narváez; Thomas R Kwapil; Tamara Sheinbaum; Elionora Peña; Neus Barrantes-Vidal; Araceli Rosa
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-02-24       Impact factor: 5.270

3.  Interaction between interleukin 3 and dystrobrevin-binding protein 1 in schizophrenia.

Authors:  Todd L Edwards; Xu Wang; Qi Chen; Brandon Wormly; Brien Riley; F Anthony O'Neill; Dermot Walsh; Marylyn D Ritchie; Kenneth S Kendler; Xiangning Chen
Journal:  Schizophr Res       Date:  2008-09-18       Impact factor: 4.939

4.  D-amino acid oxidase activity is inhibited by an interaction with bassoon protein at the presynaptic active zone.

Authors:  Michael Popiolek; John F Ross; Erik Charych; Pranab Chanda; Eckart D Gundelfinger; Stephen J Moss; Nicholas J Brandon; Mark H Pausch
Journal:  J Biol Chem       Date:  2011-06-23       Impact factor: 5.157

5.  Brain RGS4 and RGS10 protein expression in schizophrenia and depression. Effect of drug treatment.

Authors:  G Rivero; A M Gabilondo; J A García-Sevilla; L F Callado; R La Harpe; B Morentin; J J Meana
Journal:  Psychopharmacology (Berl)       Date:  2012-10-24       Impact factor: 4.530

6.  DTNBP1 is associated with imaging phenotypes in schizophrenia.

Authors:  Katherine L Narr; Philip R Szeszko; Todd Lencz; Roger P Woods; Liberty S Hamilton; Owen Phillips; Delbert Robinson; Katherine E Burdick; Pamela DeRosse; Raju Kucherlapati; Paul M Thompson; Arthur W Toga; Anil K Malhotra; Robert M Bilder
Journal:  Hum Brain Mapp       Date:  2009-11       Impact factor: 5.038

7.  A polymorphism in the dysbindin gene (DTNBP1) associated with multiple psychiatric disorders including schizophrenia.

Authors:  Joanne Voisey; Christopher D Swagell; Ian P Hughes; Jason P Connor; Bruce R Lawford; Ross M Young; C Phillip Morris
Journal:  Behav Brain Funct       Date:  2010-07-09       Impact factor: 3.759

8.  No association of dysbindin with symptom factors of schizophrenia in an Irish case-control sample.

Authors:  Sarah E Bergen; Ayman H Fanous; Po-Hsiu Kuo; Brandon K Wormley; F Anthony O'Neill; Dermot Walsh; Brien P Riley; Kenneth S Kendler
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-03-05       Impact factor: 3.568

Review 9.  The neurobiology of D-amino acid oxidase and its involvement in schizophrenia.

Authors:  L Verrall; P W J Burnet; J F Betts; P J Harrison
Journal:  Mol Psychiatry       Date:  2009-09-29       Impact factor: 15.992

10.  Dysbindin-1, a schizophrenia-related protein, functionally interacts with the DNA- dependent protein kinase complex in an isoform-dependent manner.

Authors:  Satoko Oyama; Hidekuni Yamakawa; Noboru Sasagawa; Yoshio Hosoi; Eugene Futai; Shoichi Ishiura
Journal:  PLoS One       Date:  2009-01-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.